The analysis indicated a decrease in the viral load in outpatients with mild to moderate cases of COVID-19 at a dose level of 2,800 milligrams, along with lower rates of hospitalization and emergency medical care among patients at all dose levels.
A new study shows that Covid-19 patients who were given new antibodies showed fewer symptoms and were less likely to need hospitalization or emergency medical care than those who did not receive treatment.
The second phase of the ongoing clinical trial, the provisional results of which were published in the New England Journal of Medicine, tested three different doses of LY-CoV555, a monoclonal antibody derived from the blood of a patient with COVID-19.
"For me, the most important finding was the decrease in hospitalizations," said first co-author of the study, Peter Chen, of Cedars-Sinai Medical Center in the US.
According to the researchers, monoclonal antibodies work by attaching themselves to a virus and preventing them from reproducing.
They said that LY-CoV555 binds to a specific protein on the new coronavirus, called the spike protein, which the virus needs to enter human cells and reproduce.
By preventing the virus from replicating, the scientists said the antibody slows down the reproduction process, giving the patient's immune system time to start working.
In the study, patients were given intravenous doses of either 700, 2,800, or 7,000 milligrams of the antibody, or a placebo.
The scientists wrote in the study: “In evaluating this time for a Phase 2 trial, one of the three doses of antibody equal to LY-CoV555 appears to speed up the herbal intake.decline in the viral load over time, while the other doses were not by the eleventh day."
The researchers used a pharyngeal swab to test the patients' viral load before the antibody was administered and again at several points after the drug was administered.
They also gave patients a questionnaire about symptoms and subsequent treatment.
According to the study, nearly 300 patients received the treatment (100 patients per dose level), and about 150 patients received the placebo.
Of the three dose levels, the scientists said the 2,800mg dose had been shown to be effective in reducing viral load.
By day eleventh, they said the viral load had shrunk considerably for most patients, including those in the placebo arm.
However, the researchers said that more studies are needed to validate these findings.
`` Evidence for these facts in a peer-reviewed journal provides the development of the evidence architecture for the achievable gains from neutralizing antibodies as therapies for humans that are currently identified with mild to moderate COVID-19 virus, especially patients at high risk,” said Ajay Nirola. , Another co-author of the study.
“These data demonstrate that LY-CoV555 may be effective in treating COVID-19 by reducing viral load, symptoms and the risk of outpatient hospitalization,” said Nirola.
On day 29, the study noted that hospitalization rates were only 1.6 percent in the antibody-treated group, compared to 6.3 percent in the placebo-treated group.
The researchers said the decline in hospitalizations was seen across all demographic groups, including at-risk groups - adults over the age of 65 who had a high BMI (greater than 35).
For patients at high risk, they said hospitalization rates were 4.2 per cent in patients treated with antibodies, compared to 14.6 per cent in patients treated with placebo.
The study indicated that the safety profile of patients treated with LY-CoV555 was similar to patients treated with placebo.
0 Comments